Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse
- 14 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 26 (11), 2142-2150
- https://doi.org/10.1007/s10147-021-01991-z
Abstract
Background Multiple myeloma (MM) is an incurable hematological malignancy. Despite the introduction of several novel drugs, most patients relapse. Biomarkers to identify the early signs of relapse will make it possible to adjust the therapeutic strategy before the disease worsens. Although understanding genetic changes is important for the treatment of MM, currently known biomarkers of relapse, including serum free-light chains and monoclonal paraproteins, are not associated with genetic changes. Methods We therefore performed a multicenter study to examine the usefulness of circulating cell-free DNA (cfDNA) present in the peripheral blood (PB) plasma of patients as a biomarker for MM relapse. Results We identified several driver mutations by combined analysis of next-generation sequencing and existing databases of candidate oncogenes. Furthermore, relapse was detected more sensitively by monitoring the circulating cfDNA with these driver mutations than by conventional serum free-light chain examination. Conclusion These results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.Keywords
Funding Information
- Celgene
- Japanese Society of Hematology
This publication has 26 references indexed in Scilit:
- Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myelomaLeukemia, 2016
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genesBlood, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2016
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaJournal of Clinical Oncology, 2015
- Model of translational cancer research in multiple myelomaCancer Science, 2012
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- ATP-Induced Stimulation of the Intralysosomal Hydrolysis of Thyroglobulin Evidence for an ATP-Driven Proton Pump in Thyroid LysosomesHormone and Metabolic Research, 1984